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Levels of circulating endogenous heparin in patients with 
diseases associated with inflammatory processes, such as 
asthma, are still unknown. Since heparin displays anti-
inflammatory properties, it is expected that the inhibitory 
effects on inflammatory mediators are reduced at low levels 
of endogenous heparin.1 We present evidence supporting 
the hypothesis that asthmatic patients have lower levels of 
circulating endogenous heparin than healthy individuals have.
Since 1955, endogenous plasma heparin has been 
demonstrated to be a normal constituent of blood, with 
concentrations ranging from 153 to 177 mIU/ml, and its levels 
were found to be independent of gender or age.2 Discrepancies 
in the concentrations of endogenous heparin reported by 
various research groups are thought to result from the different 
quantitative methods or isolation procedures used.
Inhaled heparin has shown potential as an anti-asthmatic 
agent. In the airways, arginine availability determines the 
production of the bronchodilator, nitric oxide. Changes in 
arginine homoeostasis may therefore cause airway hyper-
responsiveness and remodelling of the airway wall. Inhaled 
heparin was found to decrease airway hyper-responsiveness 
in early asthmatic reactions and peroxynitrite-mediated hyper-
responsiveness in late asthmatic reactions induced by a variety 
of stimuli in guinea pig and rat models of allergic asthma, as 
well as in asthmatic patients.3
The anti-allergic activity of inhaled heparin was found to be 
independent of its anticoagulant properties, where an inverse 
relationship between the molecular weight of heparin and anti-
allergic activity exists.4 In patients with a history of exercise-
induced asthma, inhaled heparin did not affect respiratory 
parameters, partial thromboplastin time or heart rate, and 
prevented post-exercise bronchoconstriction. In addition, no 
changes to bronchoconstrictor responses to histamine were 
noted. These findings suggested that heparin activity was 
associated with altering mediator release and not as a direct 
effect on smooth muscle.5
Our study was aimed at determining the levels of circulating 
plasma heparin in asthmatic patients compared with healthy 
individuals, based on the proposed role of heparin as an anti-
asthmatic agent.
Methods
Approval was obtained from the Human Ethics Committee 
of the University of the Witwatersrand for this study, which 
was conducted in collaboration with the Asthma Clinic at 
Johannesburg General Hospital.
A total of 53 controlled asthmatic patients from the Asthma 
Clinic were enrolled, and 26 healthy individuals from the 
general public agreed to participate.
Individual diagnoses of asthma were established according 
to spirometry testing: forced vital capacity, forced expiratory 
volume in one second and forced expiratory flow readings. To 
avoid interference of too many confounding variables, patients 
with a history of multiple illnesses were not approached to 
participate. Confirmed asthmatic patients with associated 
diseases such as allergic rhinitis and gastro-oesophageal reflux 
disease (GORD) were not excluded from the study.
Exclusion criteria for healthy individuals included past and 
present smokers, significant abusers of alcohol, hospitalisation 
in the previous year, taking medication (anticoagulants), and 
having suffered from the common cold in the preceding 3 
months.
Blood was sampled from the volunteers after they had given 
signed, informed consent. Heparin levels in the plasma were 
determined using the Chromogenix Coatest Heparin kit as per 
the manufacturer’s specifications. This photometric kit uses the 
chromogenic substance S-222 (Bz-Ile-Glu-(g-OR)-Gly-Arg-pNA.
HCl) as substrate.
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Background. Since heparin possesses anti-inflammatory 
properties, it is hypothesised that asthmatic patients have 
decreased levels of circulating heparin compared with healthy 
individuals.
Design. We compared endogenous heparin levels in controlled 
asthmatic patients (53 adults) from the Asthma Clinic at 
Johannesburg General Hospital with those of healthy controls 
(26 adults) from the general population. Heparin levels in the 
blood samples were tested using the Chromogenix Coatest 
Heparin kit.
Result. The blood of the patients contained significantly lower 
levels of endogenous heparin compared with that of the 
healthy individuals, indicating that the anti-inflammatory 
properties afforded by heparin are absent in these patients.
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Data analysis
Heparin levels are reported as mean ± SD of three experiments. 
The t-test was used to compare data, using GraphPad Prism 
version 3.0 at a 95% confidence limit.
Results and discussion
A total of 53 asthmatic patients were enrolled (9 males and 
44 females) and classified as suffering from mild persistent, 
moderate persistent or severe persistent asthma, based on their 
spirometry readings. Very low plasma heparin concentrations 
were determined for all asthmatic patients (2.231±0.001 mIU/
ml), these levels being on the threshold of the sensitivity of the 
assay kit. No significant differences in endogenous heparin 
levels were noted among the age groups (p=0.480) or the 
genders (p=0.786).
Of the 53 patients, 2 (3.8%) were current smokers and 9 
(16.9%) were past smokers, 30 (56.6%) were non-smokers, and 
the remaining 22.6% did not respond to this question.
A total of 15 (28.3%) patients either did not present with 
other illnesses or did not respond to this question, while 15 
(28.3%) suffered from allergic rhinitis, and 11 (20.8%) suffered 
from GORD, of whom 3 also suffered from allergic rhinitis. Of 
the 15 patients suffering from hypertension, 1 suffered from 
allergic rhinitis, while 5 also suffered from GORD.
Medications prescribed included Budeflam (budesonide), 
Asthavent (salbutamol) and Beconase (beclometasone), among 
others.
A total of 26 healthy volunteers were recruited, of whom 
10 (38.5%) were male. Our results showed that endogenous 
heparin levels did not differ significantly between the genders 
(p=0.859) or among the age groups (p=0.546), supporting the 
findings by Engelberg.1 Based on these findings, we did not 
attempt to gender- and age-match the healthy volunteers to the 
asthmatic patients.
Average plasma heparin levels in these volunteers 
(451.0±0.0248 mIU/ml) were significantly higher (p<0.001) than 
those of the asthmatic patients.
Significantly higher levels of endogenous ‘heparin-like’ 
substances were found in the plasma of atopic asthmatic 
patients, as opposed to non-allergic, non-asthmatic controls. 
It has been suggested that heparin was released to decrease 
eosinophil recruitment into allergic inflammatory sites and 
to minimise the degree of tissue damage resultant of cationic 
proteins derived from the leucocyte.4 These effects may be the 
underlying mechanism in the reduction of exercise-, histamine- 
and allergen-induced bronchoconstriction.6
These preliminary results indicate significantly decreased 
endogenous heparin levels in the asthmatic patient, thereby 
potentially decreasing anti-inflammatory effects. As it is not 
clear whether the decreased levels of heparin are a result of the 
medication (in particular β2-agonists) being administered, or a 
manifestation of the disease itself, our research is an ongoing 
endeavour to clarify this aspect.
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